BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Swain MG, Lai M, Shiffman ML, Cooksley WGE, Zeuzem S, Dieterich DT, Abergel A, Pessôa MG, Lin A, Tietz A, Connell EV, Diago M. A Sustained Virologic Response Is Durable in Patients With Chronic Hepatitis C Treated With Peginterferon Alfa-2a and Ribavirin. Gastroenterology 2010;139:1593-601. [DOI: 10.1053/j.gastro.2010.07.009] [Cited by in Crossref: 219] [Cited by in F6Publishing: 201] [Article Influence: 18.3] [Reference Citation Analysis]
Number Citing Articles
1 Rutter K, Hofer H, Beinhardt S, Dulic M, Gschwantler M, Maieron A, Laferl H, Stättermayer AF, Scherzer T, Strassl R, Holzmann H, Steindl-munda P, Ferenci P. Durability of SVR in chronic hepatitis C patients treated with peginterferon-α2a/ribavirin in combination with a direct-acting anti-viral. Aliment Pharmacol Ther 2013;38:118-23. [DOI: 10.1111/apt.12350] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
2 Shiffman ML, Long AG, James A, Alexander P. My treatment approach to chronic hepatitis C virus. Mayo Clin Proc 2014;89:934-42. [PMID: 24867397 DOI: 10.1016/j.mayocp.2014.04.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
3 Feng B, Yang RF, Xie Q, Shang J, Kong FY, Zhang HY, Rao HY, Jin Q, Cong X, Liu YY, Kang Y, Wei L. Hepatitis C virus core antigen, an earlier and stronger predictor on sustained virological response in patients with genotype 1 HCV infection. BMC Gastroenterol 2014;14:47. [PMID: 24625322 DOI: 10.1186/1471-230X-14-47] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 1.1] [Reference Citation Analysis]
4 Linas BP, Barter DM, Leff JA, Assoumou SA, Salomon JA, Weinstein MC, Kim AY, Schackman BR. The hepatitis C cascade of care: identifying priorities to improve clinical outcomes. PLoS One 2014;9:e97317. [PMID: 24842841 DOI: 10.1371/journal.pone.0097317] [Cited by in Crossref: 77] [Cited by in F6Publishing: 80] [Article Influence: 9.6] [Reference Citation Analysis]
5 Chen JY, Chung RT. Can we use the "C" word with confidence? Cure for chronic hepatitis C. Gastroenterology 2011;140:766-8. [PMID: 21256845 DOI: 10.1053/j.gastro.2011.01.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
6 AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus: HEPATITIS C VIRUS GUIDANCE PANEL. Hepatology 2015;62:932-54. [DOI: 10.1002/hep.27950] [Cited by in Crossref: 844] [Cited by in F6Publishing: 832] [Article Influence: 120.6] [Reference Citation Analysis]
7 Jensen CM, Holle LM. Ledipasvir-Sofosbuvir: A Once-Daily Oral Treatment Option for Chronic Hepatitis C Virus Genotype 1 Infection. Pharmacotherapy. 2016;36:562-574. [PMID: 27027412 DOI: 10.1002/phar.1748] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
8 Krassenburg LAP, Zanjir WR, Georgie F, Stotland E, Janssen HLA, Hansen BE, Feld JJ. Evaluation of Sustained Virologic Response as a Relevant Surrogate Endpoint for Long-term Outcomes of Hepatitis C Virus Infection. Clin Infect Dis 2021;72:780-6. [PMID: 32052014 DOI: 10.1093/cid/ciaa144] [Reference Citation Analysis]
9 Belousova V, Abd-Rabou AA, Mousa SA. Recent advances and future directions in the management of hepatitis C infections. Pharmacol Ther 2015;145:92-102. [PMID: 25200121 DOI: 10.1016/j.pharmthera.2014.09.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
10 Gentile I, Maraolo AE, Niola M, Graziano V, Borgia G, Paternoster M. Limiting the access to direct-acting antivirals against HCV: an ethical dilemma. Expert Review of Gastroenterology & Hepatology 2016;10:1227-34. [DOI: 10.1080/17474124.2016.1234375] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
11 Chen JY, Chung RT. Future classes of hepatitis C virus therapeutic agents. Infect Dis Clin North Am 2012;26:949-66. [PMID: 23083826 DOI: 10.1016/j.idc.2012.08.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
12 Liu CH, Peng CY, Kao WY, Yang SS, Shih YL, Lin CL, Tsai MK, Lee CY, Chang CC, Wu JH, Liu CJ, Su TH, Tseng TC, Chen PJ, Kao JH. Hepatitis C virus reinfection in patients on haemodialysis after achieving sustained virologic response with antiviral treatment. Aliment Pharmacol Ther 2021. [PMID: 34773272 DOI: 10.1111/apt.16697] [Reference Citation Analysis]
13 Kozbial K, Moser S, Al-Zoairy R, Schwarzer R, Datz C, Stauber R, Laferl H, Strasser M, Beinhardt S, Stättermayer AF, Gschwantler M, Zoller H, Maieron A, Graziadei I, Trauner M, Steindl-Munda P, Hofer H, Ferenci P. Follow-up of sustained virological responders with hepatitis C and advanced liver disease after interferon/ribavirin-free treatment. Liver Int 2018;38:1028-35. [PMID: 29136329 DOI: 10.1111/liv.13629] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 6.8] [Reference Citation Analysis]
14 Sapra S, Chang E, Broder MS, L'Italien G. Incidence and cost of treatment-emergent comorbid events in insured patients with chronic hepatitis C virus infection: a retrospective cohort study. BMC Health Serv Res 2014;14:429. [PMID: 25249187 DOI: 10.1186/1472-6963-14-429] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
15 Masetti C, Lleo A, Colombo M, Colombo M, Aghemo A. Postsustained Virological Response Management in Hepatitis C Patients. Semin Liver Dis 2020;40:233-9. [PMID: 32107758 DOI: 10.1055/s-0040-1702944] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Persico M, Coppola N, Rosato V, Abenavoli L, Masarone M, Luna AD. HCV antiviral therapy in injection drug users: difficult to treat or easy to cure? Annals of Hepatology 2015;14:325-32. [DOI: 10.1016/s1665-2681(19)31271-2] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
17 Klag T, Dietz J, Werner CR, Schwarz JM, Lauer UM, Beck R, Malek NP, Sarrazin C, Berg CP. Hepatitis C “true” late relapse beyond 48 weeks of sustained virologic response after direct acting antiviral therapy. Journal of Hepatology 2017;66:862-3. [DOI: 10.1016/j.jhep.2017.01.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
18 Vachon M, Perumalswami P, Dieterich DT. Hepatobiliary Manifestations of Human Immunodeficiency Virus. In: Schiff ER, Maddrey WC, Sorrell MF, editors. Schiff's Diseases of the Liver. Oxford: Wiley-Blackwell; 2011. pp. 1060-82. [DOI: 10.1002/9781119950509.ch41] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
19 Abdelrahman T, Hughes J, Main J, McLauchlan J, Thursz M, Thomson E. Reply: To PMID 24797101. Hepatology 2015;61:1438. [PMID: 25147121 DOI: 10.1002/hep.27393] [Reference Citation Analysis]
20 Edlin BR. Hepatitis C screening: getting it right. Hepatology 2013;57:1644-50. [PMID: 23239521 DOI: 10.1002/hep.26194] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
21 Pawlotsky JM. Hepatitis C virus: standard-of-care treatment. Adv Pharmacol. 2013;67:169-215. [PMID: 23886001 DOI: 10.1016/b978-0-12-405880-4.00005-6] [Cited by in Crossref: 32] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
22 Myers RP, Ramji A, Bilodeau M, Wong S, Feld JJ. An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol 2012;26:359-75. [PMID: 22720279 DOI: 10.1155/2012/947676] [Cited by in Crossref: 40] [Cited by in F6Publishing: 54] [Article Influence: 4.0] [Reference Citation Analysis]
23 Majumdar A, Kitson MT, Roberts SK. Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis. Aliment Pharmacol Ther. 2016;43:1276-1292. [PMID: 27087015 DOI: 10.1111/apt.13633] [Cited by in Crossref: 95] [Cited by in F6Publishing: 91] [Article Influence: 15.8] [Reference Citation Analysis]
24 Morisco F, Granata R, Stroffolini T, Guarino M, Donnarumma L, Gaeta L, Loperto I, Gentile I, Auriemma F, Caporaso N. Sustained virological response: A milestone in the treatment of chronic hepatitis C. World J Gastroenterol 2013; 19(18): 2793-2798 [PMID: 23687416 DOI: 10.3748/wjg.v19.i18.2793] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 49] [Article Influence: 5.0] [Reference Citation Analysis]
25 Alghamdi AS, Alghamdi M, Sanai FM, Alghamdi H, Aba-Alkhail F, Alswat K, Babatin M, Alqutub A, Altraif I, Alfaleh F. SASLT guidelines: Update in treatment of Hepatitis C virus infection. Saudi J Gastroenterol 2016;22 Suppl:S25-57. [PMID: 27538727 DOI: 10.4103/1319-3767.188067] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
26 Costa VD, Brandão-Mello CE, Nunes EP, Dos Santos Silva PGC, de Souza Rodrigues LLLX, Lampe E, do Amaral Mello FC. Treatment of chronic HCV infection with DAAs in Rio de Janeiro/Brazil: SVR rates and baseline resistance analyses in NS5A and NS5B genes. PLoS One 2019;14:e0216327. [PMID: 31063475 DOI: 10.1371/journal.pone.0216327] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
27 Fouad M, El Kassas M, Ahmed E, El Sheemy R. Tumor characteristics of hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C: Comparative analysis with antiviral therapy-naive patients. World J Hepatol 2021; 13(11): 1743-1752 [PMID: 34904042 DOI: 10.4254/wjh.v13.i11.1743] [Reference Citation Analysis]
28 Adler H, Lambert JS. Daclatasvir for the treatment of hepatitis C virus infection. Expert Rev Gastroenterol Hepatol. 2014;8:725-738. [PMID: 24882552 DOI: 10.1586/17474124.2014.925798] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
29 Mishra A, Younossi Z. Commentary: durability of SVR in chronic hepatitis C patients treated with peginterferon-a2a/ribavirin in combination with a direct-acting anti-viral. Aliment Pharmacol Ther 2013;38:557-8. [PMID: 23937466 DOI: 10.1111/apt.12419] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
30 Wedemeyer H, Reimer J, Sandow P, Hueppe D, Lutz T, Gruengreiff K, Goelz J, Christensen S, Pfeiffer-Vornkahl H, Alshuth U, Manns MP. Long-term outcome of chronic hepatitis C virus infection in a real-world setting: The German LOTOS study. Liver Int 2017;37:1468-75. [PMID: 28247572 DOI: 10.1111/liv.13399] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
31 Shiffman ML, Gunn NT. Management and Treatment of Chronic HBV and HCV Co-Infection and the Impact of Anti-Viral Therapy. Curr Hepatology Rep 2017;16:169-77. [DOI: 10.1007/s11901-017-0352-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
32 Fofiu C, Boeriu A, Coman F, Fofiu A, Panic N, Bulajic M, Dobru D. Interferon-Free Regimen: Equally Effective in Treatment Naive and Experienced HCV Patients. Ann Hepatol 2019;18:137-43. [PMID: 31113582 DOI: 10.5604/01.3001.0012.7905] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
33 Lu Y, Andonov A, Wong DK. Hepatitis C virus late relapse after sustained virologic response from interferon and ribavirin treatment as confirmed by RNA sequencing. J Clin Microbiol 2014;52:367-9. [PMID: 24172153 DOI: 10.1128/JCM.01367-13] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
34 Leask JD, Dillon JF. Review article: treatment as prevention - targeting people who inject drugs as a pathway towards hepatitis C eradication. Aliment Pharmacol Ther. 2016;44:145-156. [PMID: 27199103 DOI: 10.1111/apt.13673] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
35 Chao D, Botwin GJ, Morgan TR. Update on Recently Approved Treatments for Hepatitis C. Curr Treat Options Gastro 2014;12:211-28. [DOI: 10.1007/s11938-014-0013-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
36 Weber J, Sahoo MK, Taylor N, Shi RZ, Pinsky BA. Evaluation of the Aptima HCV Quant Dx Assay Using Serum and Dried Blood Spots. J Clin Microbiol 2019;57:e00030-19. [PMID: 30760534 DOI: 10.1128/JCM.00030-19] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
37 Fabrizi F, Martin P, Messa P. New treatment for hepatitis C in chronic kidney disease, dialysis, and transplant. Kidney Int. 2016;89:988-994. [PMID: 27083277 DOI: 10.1016/j.kint.2016.01.011] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 5.5] [Reference Citation Analysis]
38 De Sanctis V, Soliman AT, Daar S, Alansary N, Kattamis A, Skafida M, Galati MC, Christou S, Campisi S, Messina G, Yassin MA, Canatan D, Di Maio S, Al Jaouni S, Raiola G, Karimi M, Kaleva V, Kakkar S, Mariannis D, Kattamis C. A Concise Review on the Frequency, Major Risk Factors and Surveillance of Hepatocellular Carcinoma (HCC) in β-Thalassemias: Past, Present and Future Perspectives and the ICET-A Experience. Mediterr J Hematol Infect Dis 2020;12:e2020006. [PMID: 31934316 DOI: 10.4084/MJHID.2020.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
39 Sussman NL, Remien CH, Kanwal F. The end of hepatitis C. Clin Gastroenterol Hepatol 2014;12:533-6. [PMID: 24480676 DOI: 10.1016/j.cgh.2014.01.025] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
40 European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2014;60:392-420. [PMID: 24331294 DOI: 10.1016/j.jhep.2013.11.003] [Cited by in Crossref: 600] [Cited by in F6Publishing: 564] [Article Influence: 66.7] [Reference Citation Analysis]
41 Chevaliez S. Virological tools to diagnose and monitor hepatitis C virus infection. Clin Microbiol Infect. 2011;17:116-121. [PMID: 21054664 DOI: 10.1111/j.1469-0691.2010.03418.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 3.3] [Reference Citation Analysis]
42 Sadler MD, Lee SS. Revolution in hepatitis C antiviral therapy. Br Med Bull. 2015;113:31-44. [PMID: 25680808 DOI: 10.1093/bmb/ldv004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
43 Haber B, Alonso E, Pedreira A, Rodriguez-Baez N, Ciocca M, Lacaille F, Lang T, Gonzalez T, Goodman Z, Yang Z. Long-Term Follow-Up of Children Treated With Peginterferon and Ribavirin for Hepatitis C Virus Infection. J Pediatr Gastroenterol Nutr. 2017;64:89-94. [PMID: 27111344 DOI: 10.1097/mpg.0000000000001239] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
44 Fayek SA, Quintini C, Chavin KD, Marsh CL. The Current State of Liver Transplantation in the United States: Perspective From American Society of Transplant Surgeons (ASTS) Scientific Studies Committee and Endorsed by ASTS Council. Am J Transplant 2016;16:3093-104. [PMID: 27545282 DOI: 10.1111/ajt.14017] [Cited by in Crossref: 57] [Cited by in F6Publishing: 44] [Article Influence: 9.5] [Reference Citation Analysis]
45 Kim KA. [Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Indications for Treatment]. Korean J Gastroenterol 2016;67:123-6. [PMID: 26996180 DOI: 10.4166/kjg.2016.67.3.123] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
46 Mariño Z, Lens S, Gambato M, Forns X. Advances in hepatitis C therapies. Expert Opin Pharmacother 2015;16:1929-43. [PMID: 26219918 DOI: 10.1517/14656566.2015.1070828] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
47 Chen M, Chen M, Tsai C, Chou C, Lin H, Huang D, Huang Y. Incidence and antiviral response of hepatitis C virus reactivation in lupus patients undergoing immunosuppressive therapy. Lupus 2015;24:1029-36. [DOI: 10.1177/0961203315571465] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
48 Zayed RA, Omran D, Zayed AA, Elmessery LO. Determinants of Infection Outcome in HCV-Genotype 4. Viral Immunol. 2017;30:560-567. [PMID: 28731371 DOI: 10.1089/vim.2017.0071] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
49 Qing S, Ji D, Li B, Li F, Wang Y, Niu X, Ling B, Meng Y, Lau G, Chen G. Improvement of glucose and lipid metabolism with pegylated interferon-a plus ribavirin therapy in Chinese patients chronically infected with genotype 1b hepatitis C virus. Ann Saudi Med 2015;35:293-7. [PMID: 26497709 DOI: 10.5144/0256-4947.2015.293] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
50 Shengir M, Elgara M, Sebastiani G. Metabolic and cardiovascular complications after virological cure in hepatitis C: What awaits beyond. World J Gastroenterol 2021; 27(17): 1959-1972 [PMID: 34007133 DOI: 10.3748/wjg.v27.i17.1959] [Reference Citation Analysis]
51 Sirinawasatien A, Techasirioangkun T. Sofosbuvir-based regimens in the treatment of patients with chronic hepatitis C virus infection: Real-world efficacy in Thailand. PLoS One 2020;15:e0229517. [PMID: 32106270 DOI: 10.1371/journal.pone.0229517] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
52 Pawlotsky JM. Treatment of chronic hepatitis C: current and future. Curr Top Microbiol Immunol 2013;369:321-42. [PMID: 23463207 DOI: 10.1007/978-3-642-27340-7_13] [Cited by in Crossref: 17] [Cited by in F6Publishing: 38] [Article Influence: 1.9] [Reference Citation Analysis]
53 Innes HA, Hutchinson SJ, Allen S, Bhattacharyya D, Bramley P, Delahooke TE, Dillon JF, Forrest E, Fraser A, Gillespie R, Goldberg DJ, Kennedy N, Mcdonald S, Mcleod A, Mills PR, Morris J, Hayes P; on behalf of the Hepatitis C Clinical Database Monitoring Committee. Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care. Hepatology 2011;54:1547-58. [DOI: 10.1002/hep.24561] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 4.2] [Reference Citation Analysis]
54 Boisvert M, Shoukry NH. Type III Interferons in Hepatitis C Virus Infection. Front Immunol 2016;7:628. [PMID: 28066437 DOI: 10.3389/fimmu.2016.00628] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
55 Coppola N, Pisaturo M, Tonziello G, Sagnelli C, Sagnelli E, Angelillo IF. Efficacy of Pegylated interferon α-2a and α-2b in patients with genotype 1 chronic hepatitis C: a meta-analysis. BMC Infect Dis. 2012;12:357. [PMID: 23245594 DOI: 10.1186/1471-2334-12-357] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 2.9] [Reference Citation Analysis]
56 Odhiambo R, Chhatwal J, Ferrante SA, El Khoury A, Elbasha E. Economic Evaluation of Boceprevir for the Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus Infection in Hungary. JHEOR 2013;1:62-82. [DOI: 10.36469/9854] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
57 Kim K. Durability of a sustained virologic response in patients with chronic hepatitis C treated with peginterferon and ribavirin. Korean J Hepatol 2011;17:84. [DOI: 10.3350/kjhep.2011.17.1.84] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
58 van der Meer AJ. Achieving sustained virological response: what’s the impact on further hepatitis C virus-related disease? Expert Review of Gastroenterology & Hepatology 2015;9:559-66. [DOI: 10.1586/17474124.2015.1001366] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
59 De Clercq E. The race for interferon-free HCV therapies: a snapshot by the spring of 2012: Interferon-free HCV therapies. Rev Med Virol 2012;22:392-411. [DOI: 10.1002/rmv.1727] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
60 Verma S, Ide K, Shimizu S, Das LK, Tahara H, Ohira M, Ishiyama K, Tanaka Y, Tashiro H, Ohdan H. Kidney transplantation from an anti-hepatitis C virus antibody-positive donor into an anti-hepatitis C virus antibody-negative recipient: A case report. Transplantation Reports 2016;1:4-6. [DOI: 10.1016/j.tpr.2016.05.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
61 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu.; European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018;69:461-511. [PMID: 29650333 DOI: 10.1016/j.jhep.2018.03.026] [Cited by in Crossref: 905] [Cited by in F6Publishing: 751] [Article Influence: 226.3] [Reference Citation Analysis]
62 Jang JY, Chung RT. Chronic hepatitis C. Gut Liver. 2011;5:117-132. [PMID: 21814590 DOI: 10.5009/gnl.2011.5.2.117] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
63 Sims OT, Womack BG. Hepatitis C and HIV Coinfection for Social Workers in Public Health, Medical and Substance Use Treatment Settings. Soc Work Public Health 2015;30:325-35. [PMID: 25811121 DOI: 10.1080/19371918.2014.1000506] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
64 European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015;63:199-236. [PMID: 25911336 DOI: 10.1016/j.jhep.2015.03.025] [Cited by in Crossref: 814] [Cited by in F6Publishing: 766] [Article Influence: 116.3] [Reference Citation Analysis]
65 Calner P, Sperring H, Ruiz-Mercado G, Miller NS, Andry C, Battisti L, Scrudder K, Shea F, Chan A, Schechter-Perkins EM. HCV screening, linkage to care, and treatment patterns at different sites across one academic medical center. PLoS One 2019;14:e0218388. [PMID: 31291275 DOI: 10.1371/journal.pone.0218388] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
66 Wilby KJ, Partovi N, Ford JA, Greanya E, Yoshida EM. Review of boceprevir and telaprevir for the treatment of chronic hepatitis C. Can J Gastroenterol 2012;26:205-10. [PMID: 22506260 DOI: 10.1155/2012/751057] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 3.7] [Reference Citation Analysis]
67 von Köckritz L, Dufour JF. Management of chronic hepatitis C in 2017. Hamostaseologie 2017;37:186-95. [PMID: 27896359 DOI: 10.5482/HAMO-16-07-0019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
68 Aqel BA, Vargas HE. Hepatitis C virus infection in nonliver solid organ transplant candidates and recipients. Curr Opin Organ Transplant 2015;20:259-66. [PMID: 25944237 DOI: 10.1097/MOT.0000000000000195] [Cited by in Crossref: 4] [Article Influence: 0.6] [Reference Citation Analysis]
69 Gimeno-Ballester V, Simón MÁ, Trigo C, Mar J, San Miguel R. Sofosbuvir plus simeprevir for the treatment of genotype 1 chronic hepatitis C: a review of evidence. Expert Rev Gastroenterol Hepatol 2016;10:1289-303. [PMID: 27626505 DOI: 10.1080/17474124.2016.1236682] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
70 Wigneswaran J, Van Wyck D, Pegues D, Gholam P, Nissenson AR. Hepatitis C virus infection in patients with end-stage renal disease: Hepatitis C in renal patients. Hemodialysis International 2018;22:297-307. [DOI: 10.1111/hdi.12672] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
71 Johnson TL, Toliver JC, Mao L, Oramasionwu CU. Differences in outpatient care and treatment utilization for patients with HIV/HCV coinfection, HIV, and HCV monoinfection, a cross-sectional study. BMC Infect Dis. 2014;14:217. [PMID: 24755037 DOI: 10.1186/1471-2334-14-217] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
72 Ng V, Saab S. Effects of a sustained virologic response on outcomes of patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2011;9:923-30. [PMID: 21699815 DOI: 10.1016/j.cgh.2011.05.028] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 4.6] [Reference Citation Analysis]
73 Chen W, Ward T, Tan MP, Yan J, Wang PF, Wygant GD, Gordon J. Daclatasvir combined with asunaprevir is a cost-effective and cost-saving treatment for hepatitis C infection in China. J Comp Eff Res 2018;7:785-95. [PMID: 29860879 DOI: 10.2217/cer-2018-0005] [Reference Citation Analysis]
74 Terrault NA, Hassanein TI. Management of the patient with SVR. Journal of Hepatology 2016;65:S120-9. [DOI: 10.1016/j.jhep.2016.08.001] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 5.5] [Reference Citation Analysis]
75 Pessôa MG, Cheinquer H, Almeida PR, Silva GF, Lima MPJ, Paraná R, Lacerda MA, Parise ER, Pernambuco JR, Pedrosa SS, Teixeira R, Sette H, Tatsch F. Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial. Annals of Hepatology 2012;11:52-61. [DOI: 10.1016/s1665-2681(19)31486-3] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
76 Rutter K, Stättermayer AF, Beinhardt S, Scherzer T, Steindl-munda P, Trauner M, Ferenci P, Hofer H. Successful anti-viral treatment improves survival of patients with advanced liver disease due to chronic hepatitis C. Aliment Pharmacol Ther 2015;41:521-31. [DOI: 10.1111/apt.13085] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 4.4] [Reference Citation Analysis]
77 Chevaliez S, Asselah T. Mechanisms of non-response to antiviral treatment in chronic hepatitis C. Clin Res Hepatol Gastroenterol. 2011;35 Suppl 1:S31-S41. [PMID: 21742299 DOI: 10.1016/s2210-7401(11)70005-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
78 Smith-Palmer J, Cerri K, Valentine W. Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits. BMC Infect Dis. 2015;15:19. [PMID: 25596623 DOI: 10.1186/s12879-015-0748-8] [Cited by in Crossref: 105] [Cited by in F6Publishing: 96] [Article Influence: 15.0] [Reference Citation Analysis]
79 Buti M, Esteban R. Preparing the patient for success: Treat or wait? Digestive and Liver Disease 2013;45:S332-6. [DOI: 10.1016/j.dld.2013.07.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
80 Martin TC, Singh GJ, McClure M, Nelson M. HCV reinfection among HIV-positive men who have sex with men: a pragmatic approach. Hepatology. 2015;61:1437. [PMID: 25147047 DOI: 10.1002/hep.27391] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
81 Manns MP, von Hahn T. Novel therapies for hepatitis C — one pill fits all? Nat Rev Drug Discov 2013;12:595-610. [DOI: 10.1038/nrd4050] [Cited by in Crossref: 140] [Cited by in F6Publishing: 132] [Article Influence: 15.6] [Reference Citation Analysis]
82 Chen Y, Jiao B, Yao M, Shi X, Zheng Z, Li S, Chen L. ISG12a inhibits HCV replication and potentiates the anti-HCV activity of IFN-α through activation of the Jak/STAT signaling pathway independent of autophagy and apoptosis. Virus Res 2017;227:231-9. [PMID: 27777077 DOI: 10.1016/j.virusres.2016.10.013] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
83 Fabrizi F, Messa P. Therapy of hepatitis C by direct-acting anti-virals: the end of HCV in dialysis population? Expert Rev Clin Pharmacol. 2015;8:785-793. [PMID: 26365524 DOI: 10.1586/17512433.2015.1086266] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
84 Mak LY, Seto WK, Lai CL, Yuen MF. An update on the toxicological considerations for protease inhibitors used for hepatitis C infection. Expert Opin Drug Metab Toxicol 2018;14:483-91. [PMID: 29718748 DOI: 10.1080/17425255.2018.1472236] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
85 Habib S, Azam M, Siddiqui AH, Rajdev K, Chalhoub M. Hepatocellular Carcinoma After Successful Treatment of Hepatitis C Virus with Ledipasvir/Sofosbuvir Presenting as Acute Pulmonary Tumor Embolism. Cureus 2019;11:e4336. [PMID: 31187001 DOI: 10.7759/cureus.4336] [Reference Citation Analysis]
86 Castillo I, Bartolomé J, Quiroga JA, Barril G, Carreño V. Long-term virological follow up of patients with occult hepatitis C virus infection. Liver Int 2011;31:1519-24. [PMID: 22093326 DOI: 10.1111/j.1478-3231.2011.02613.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
87 Aghemo A, Lampertico P, Colombo M. Assessing long-term treatment efficacy in chronic hepatitis B and C: Between evidence and common sense. Journal of Hepatology 2012;57:1326-35. [DOI: 10.1016/j.jhep.2012.06.025] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
88 Simmons B, Saleem J, Hill A, Riley RD, Cooke GS. Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis. Clin Infect Dis. 2016;62:683-694. [PMID: 26787172 DOI: 10.1093/cid/civ948] [Cited by in Crossref: 178] [Cited by in F6Publishing: 163] [Article Influence: 29.7] [Reference Citation Analysis]
89 . EASL Recommendations on Treatment of Hepatitis C 2014. Journal of Hepatology 2014;61:373-95. [DOI: 10.1016/j.jhep.2014.05.001] [Cited by in Crossref: 128] [Cited by in F6Publishing: 134] [Article Influence: 16.0] [Reference Citation Analysis]
90 European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol. 2017;66:153-194. [PMID: 27667367 DOI: 10.1016/j.jhep.2016.09.001] [Cited by in Crossref: 712] [Cited by in F6Publishing: 649] [Article Influence: 118.7] [Reference Citation Analysis]
91 Lawitz EJ, Membreno FE. Response-guided therapy in patients with genotype 1 hepatitis C virus: current status and future prospects. J Gastroenterol Hepatol. 2014;29:1574-1581. [PMID: 24852401 DOI: 10.1111/jgh.12632] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
92 Gürbüz Y, Tülek NE, Tütüncü EE, Koruk ST, Aygen B, Demirtürk N, Kınıklı S, Kaya A, Yıldırmak T, Süer K, Korkmaz F, Ural O, Akhan S, Günal Ö, Tuna N, Köse Ş, Gönen İ, Örmen B, Türker N, Saltoğlu N, Batırel A, Tuncer G, Bulut C, Sırmatel F, Ulçay A, Karagöz E, Tosun D, Şener A, Aynıoğlu A, Altunok ES. Evaluation of Dual Therapy in Real Life Setting in Treatment-Naïve Turkish Patients with HCV Infection: A Multicenter, Retrospective Study. Balkan Med J 2016;33:18-26. [PMID: 26966614 DOI: 10.5152/balkanmedj.2015.15859] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
93 Hajiaghamohammadi A, Samimi R, Miroliaee A, Kazemifar AM, Nazem M. Treatment outcome in chronic hepatitis C infection: a four years survey among Iranian patients. Glob J Health Sci 2014;7:75-81. [PMID: 25948447 DOI: 10.5539/gjhs.v7n3p75] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
94 Young J, Rossi C, Gill J, Walmsley S, Cooper C, Cox J, Martel-Laferriere V, Conway B, Pick N, Vachon ML, Klein MB; Canadian Co-infection Cohort Investigators. Risk Factors for Hepatitis C Virus Reinfection After Sustained Virologic Response in Patients Coinfected With HIV. Clin Infect Dis 2017;64:1154-62. [PMID: 28199495 DOI: 10.1093/cid/cix126] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 10.0] [Reference Citation Analysis]
95 Shiffman ML, James AM, Long AG, Alexander PC. Treatment of chronic HCV with sofosbuvir and simeprevir in patients with cirrhosis and contraindications to interferon and/or ribavirin. Am J Gastroenterol. 2015;110:1179-1185. [PMID: 26215530 DOI: 10.1038/ajg.2015.218] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
96 Shaheen MA, Idrees M. Evidence-based consensus on the diagnosis, prevention and management of hepatitis C virus disease. World J Hepatol 2015; 7(3): 616-627 [PMID: 25848486 DOI: 10.4254/wjh.v7.i3.616] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
97 Myers RP, Shah H, Burak KW, Cooper C, Feld JJ. An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol Hepatol 2015;29:19-34. [PMID: 25585348 DOI: 10.1155/2015/692408] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 6.7] [Reference Citation Analysis]
98 Wiśniewska-Ligier M, Pawłowska M, Pilarczyk M, Halota W, Woźniakowska-Gęsicka T. Efficacy of pegylated interferon α-2b and ribavirin in chronic hepatitis C virus (genotypes 1 and 4) infection. J Pediatr Gastroenterol Nutr 2013;57:694-9. [PMID: 23942001 DOI: 10.1097/MPG.0b013e3182a7d91e] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
99 Myers RP, Cooper C, Sherman M, Lalonde R, Witt-Sullivan H, Elkashab M, Harris P, Balshaw R, Usaty C, Marrotta PJ. Outcomes of chronic hepatitis C therapy in patients treated in community versus academic centres in Canada: final results of APPROACH (a prospective study of peginterferon alfa-2a and ribavirin at academic and community centres in Canada). Can J Gastroenterol 2011;25:503-10. [PMID: 21912762 DOI: 10.1155/2011/698780] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
100 Mohamed HZ, Sabri NA, Zaki HM, Shaheen SM. Clinical effects of simvastatin in chronic hepatitis C patients receiving sofosbuvir/daclatasvir combination. A randomized, placebo-controlled, double-blinded study. Clin Exp Hepatol 2020;6:99-105. [PMID: 32728626 DOI: 10.5114/ceh.2020.95566] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
101 Zhu J, Hazen RJ, Joyce C, Delpino A, Kirkham HS, Strickland CD, Markes-wilson S, Kim T, Kang M, Rubin RA, Stein LL. Local specialty pharmacy and specialty clinic collaboration assists access to hepatitis C direct-acting antivirals. Journal of the American Pharmacists Association 2018;58:89-93.e2. [DOI: 10.1016/j.japh.2017.10.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
102 Strader DB, Seeff LB. A brief history of the treatment of viral hepatitis C. Clin Liver Dis. 2012;1:6-11. [PMID: 31186837 DOI: 10.1002/cld.1] [Cited by in Crossref: 28] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
103 Dillon JF, Lazarus JV, Razavi HA. Urgent action to fight hepatitis C in people who inject drugs in Europe. Hepatol Med Policy. 2016;1:2. [PMID: 30288305 DOI: 10.1186/s41124-016-0011-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
104 Chen S, Li S, Chen L. Interferon-inducible Protein 6-16 (IFI-6-16, ISG16) promotes Hepatitis C virus replication in vitro: Interferon-Inducible Protein 6-16 (IFI-6-16, ISG16). J Med Virol 2016;88:109-14. [DOI: 10.1002/jmv.24302] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
105 Ward T, Webster S, Mishina S, McEwan P, Wygant G, Wang F. Assessing the Budget Impact and Economic Outcomes of the Introduction of Daclatasvir + Asunaprevir and Sofosbuvir/Ledipasvir for the Treatment of Chronic Hepatitis C Virus Infection in Japan. Value Health Reg Issues. 2017;12:1-6. [PMID: 28648305 DOI: 10.1016/j.vhri.2016.10.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
106 Puchades Renau L, Berenguer M. Introduction to hepatitis C virus infection: Overview and history of hepatitis C virus therapies: Overview and history of hepatitis C therapies. Hemodialysis International 2018;22:S8-S21. [DOI: 10.1111/hdi.12647] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
107 Shin SK, Lee JW, Ra H, Kwon OS, Shin JB, Jin YJ, Lee S, Han KJ, Kim YN, Kim TH, Kim YS, Kim JH. Durability of Sustained Virologic Response and Improvement of Fibrosis Markers after Daclatasvir and Asunaprevir Treatment in Genotype 1b Hepatitis C Virus-Infected Patients: a Real Life and Multicenter Study. J Korean Med Sci 2019;34:e264. [PMID: 31650719 DOI: 10.3346/jkms.2019.34.e264] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
108 Satoskar R, Reau N. Potential consequences of healthcare recommendations: a focus on the U.S. Preventive Services Task Force. Hepatology 2013;58:422-7. [PMID: 23460345 DOI: 10.1002/hep.26349] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
109 Gordon SC, Pockros PJ, Terrault NA, Hoop RS, Buikema A, Nerenz D, Hamzeh FM. Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection. Hepatology. 2012;56:1651-1660. [PMID: 22610658 DOI: 10.1002/hep.25842] [Cited by in Crossref: 77] [Cited by in F6Publishing: 72] [Article Influence: 7.7] [Reference Citation Analysis]
110 Manns MP, Buti M, Gane E, Pawlotsky JM, Razavi H, Terrault N, Younossi Z. Hepatitis C virus infection. Nat Rev Dis Primers. 2017;3:17006. [PMID: 28252637 DOI: 10.1038/nrdp.2017.6] [Cited by in Crossref: 189] [Cited by in F6Publishing: 162] [Article Influence: 37.8] [Reference Citation Analysis]
111 Fabrizi F, Messa P. Managing hepatitis C therapy failures and chronic kidney disease. Expert Rev Clin Pharmacol 2018;11:1135-42. [PMID: 30309263 DOI: 10.1080/17512433.2018.1534202] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
112 Lopez Angel CJ, Pham EA, Du H, Vallania F, Fram BJ, Perez K, Nguyen T, Rosenberg-Hasson Y, Ahmed A, Dekker CL, Grant PM, Khatri P, Maecker HT, Glenn JS, Davis MM, Furman D. Signatures of immune dysfunction in HIV and HCV infection share features with chronic inflammation in aging and persist after viral reduction or elimination. Proc Natl Acad Sci U S A 2021;118:e2022928118. [PMID: 33811141 DOI: 10.1073/pnas.2022928118] [Reference Citation Analysis]
113 Kurokawa K, Ohki T, Kato J, Fukumura Y, Imai M, Shibata C, Arai J, Kondo M, Takagi K, Kojima K, Seki M, Mori M, Toda N, Tagawa K. Hepatitis C virus relapse after successful treatment with direct-acting antivirals, followed by sarcomatous changes in hepatocellular carcinoma: a case report. J Med Case Rep 2020;14:62. [PMID: 32456712 DOI: 10.1186/s13256-020-02392-y] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
114 Manns MP, Vierling JM, Bacon BR, Bruno S, Shibolet O, Baruch Y, Marcellin P, Caro L, Howe AY, Fandozzi C, Gress J, Gilbert CL, Shaw PM, Cooreman MP, Robertson MN, Hwang P, Dutko FJ, Wahl J, Mobashery N. The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis. Gastroenterology 2014;147:366-76.e6. [PMID: 24727022 DOI: 10.1053/j.gastro.2014.04.006] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 4.5] [Reference Citation Analysis]
115 Moon C, Jung KS, Kim DY, Baatarkhuu O, Park JY, Kim BK, Kim SU, Ahn SH, Han KH. Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin. Dig Dis Sci. 2015;60:573-581. [PMID: 25236421 DOI: 10.1007/s10620-014-3361-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
116 Cortez KJ, Kottilil S. Beyond interferon: rationale and prospects for newer treatment paradigms for chronic hepatitis C. Ther Adv Chronic Dis. 2015;6:4-14. [PMID: 25553238 DOI: 10.1177/2040622314551934] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 4.4] [Reference Citation Analysis]
117 Pruß A, Chandrasekar A, Sánchez-Ibáñez J, Lucas-Samuel S, Kalus U, Rabenau HF. Algorithms for the Testing of Tissue Donors for Human Immunodeficiency Virus, Hepatitis B Virus, and Hepatitis C Virus. Transfus Med Hemother 2021;48:12-22. [PMID: 33708048 DOI: 10.1159/000513179] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
118 Lin CC, Su SH, Jeng WJ, Huang CH, Teng W, Chen WT, Chen YC, Lin CY, Sheen IS. CCL4 is the only predictor for non-responder in GT-1 CHC patients with favorable IL28B genotype when treated with PegIFN/RBV. BMC Gastroenterol 2017;17:169. [PMID: 29284412 DOI: 10.1186/s12876-017-0724-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
119 van der Meer AJ, Wedemeyer H, Feld JJ, Hansen BE, Manns MP, Zeuzem S, Janssen HL. Is there sufficient evidence to recommend antiviral therapy in hepatitis C? J Hepatol. 2014;60:191-196. [PMID: 23973931 DOI: 10.1016/j.jhep.2013.07.043] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
120 Chevaliez S, Hézode C, Soulier A, Costes B, Bouvier-Alias M, Rouanet S, Foucher J, Bronowicki JP, Tran A, Rosa I, Mathurin P, Alric L, Leroy V, Couzigou P, Mallat A, Charaf-Eddine M, Babany G, Pawlotsky JM. High-dose pegylated interferon-α and ribavirin in nonresponder hepatitis C patients and relationship with IL-28B genotype (SYREN trial). Gastroenterology 2011;141:119-27. [PMID: 21439960 DOI: 10.1053/j.gastro.2011.03.039] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
121 Mitchell RA, Hussaini T, Yau AH, Krajden M, Wright AJ, Scudamore CH, Marquez Azalgara V, Erb SR, Yoshida EM. Transplantation of a Liver Allograft From a Hepatitis C Virus Seropositive Donor With Previous Sustained Virologic Response to an Uninfected Recipient Suffering Steroid Refractory Acute Graft Rejection With No Evidence of HCV Transmission. Transplant Direct 2018;4:e347. [PMID: 29707618 DOI: 10.1097/TXD.0000000000000763] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
122 Lapointe-Shaw L, Georgie F, Carlone D, Cerocchi O, Chung H, Dewit Y, Feld JJ, Holder L, Kwong JC, Sander B, Flemming JA. Identifying cirrhosis, decompensated cirrhosis and hepatocellular carcinoma in health administrative data: A validation study. PLoS One 2018;13:e0201120. [PMID: 30133446 DOI: 10.1371/journal.pone.0201120] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 9.5] [Reference Citation Analysis]
123 Hofmann WP, Zeuzem S. A new standard of care for the treatment of chronic HCV infection. Nat Rev Gastroenterol Hepatol 2011;8:257-64. [PMID: 21468124 DOI: 10.1038/nrgastro.2011.49] [Cited by in Crossref: 92] [Cited by in F6Publishing: 93] [Article Influence: 8.4] [Reference Citation Analysis]
124 Ferenci P. Viral hepatitis: cure of chronic hepatitis C--required length of follow-up? Nat Rev Gastroenterol Hepatol 2015;12:10-1. [PMID: 25421584 DOI: 10.1038/nrgastro.2014.198] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
125 Putra J, Schiano TD, Fiel MI. Histological assessment of the liver explant in transplanted hepatitis C virus patients achieving sustained virological response with direct-acting antiviral agents. Histopathology. 2018;72:990-996. [PMID: 29235144 DOI: 10.1111/his.13453] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
126 Han QY, Liu ZW. Current treatment of chronic hepatitis C in China: Dilemma and potential problems. World J Gastroenterol 2016; 22(19): 4615-4618 [PMID: 27217693 DOI: 10.3748/wjg.v22.i19.4615] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
127 Pearlman BL, Ehleben C. Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obviates a protease inhibitor. Hepatology. 2014;59:71-77. [PMID: 23873583 DOI: 10.1002/hep.26624] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 3.4] [Reference Citation Analysis]
128 Huang P, Wang Y, Yue M, Ge Z, Xia X, Jeyarajan AJ, Holmes JA, Yu R, Zhu C, Yang S, Lin W, Chung RT. The risk of hepatitis C virus recurrence in hepatitis C virus-infected patients treated with direct-acting antivirals after achieving a sustained virological response: A comprehensive analysis. Liver Int 2021. [PMID: 34051040 DOI: 10.1111/liv.14976] [Reference Citation Analysis]
129 Hayashi K, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Hirooka Y, Toyoda H, Kumada T, Hattori M, Katano Y, Goto H. Late relapse of hepatitis C virus in patients with sustained virological response after daclatasvir and asunaprevir therapy. J Viral Hepat 2018;25:1446-51. [PMID: 29993164 DOI: 10.1111/jvh.12967] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
130 Zeng QL, Feng GH, Zhang JY, Chen Y, Yang B, Huang HH, Zhang XX, Zhang Z, Wang FS. Risk factors for liver-related mortality in chronic hepatitis C patients: A deceased case-living control study. World J Gastroenterol 2014; 20(18): 5519-5526 [PMID: 24833882 DOI: 10.3748/wjg.v20.i18.5519] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
131 Wiktor SZ, Scott JD. What is the impact of treatment for hepatitis C virus infection? Lancet 2017;390:107-9. [PMID: 28699578 DOI: 10.1016/S0140-6736(17)31762-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 2.3] [Reference Citation Analysis]
132 Godofsky E. Why Should Infectious Disease Physicians Care for the Hepatitis C–Infected Patient? Infectious Disease Clinics of North America 2012;26:839-47. [DOI: 10.1016/j.idc.2012.08.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
133 Howe AY, Long J, Nickle D, Barnard R, Thompson S, Howe J, Alves K, Wahl J. Long-term follow-up of patients receiving boceprevir for treatment of chronic hepatitis C. Antiviral Res 2015;113:71-8. [PMID: 25446895 DOI: 10.1016/j.antiviral.2014.10.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
134 Aiza-Haddad I, Ballesteros-Amozurrutia A, Borjas-Almaguer OD, Castillo-Barradas M, Castro-Narro G, Chávez-Tapia N, Chirino-Sprung RA, Cisneros-Garza L, Dehesa-Violante M, Flores-Calderón J, Flores-Gaxiola A, García-Juárez I, González-Huezo MS, González-Moreno EI, Higuera-de la Tijera F, Kershenobich-Stalnikowitz D, López-Méndez E, Malé-Velázquez R, Marín-López E, Mata-Marín JA, Méndez-Sánchez N, Monreal-Robles R, Moreno-Alcántar R, Muñoz-Espinosa L, Navarro-Alvarez S, Pavia-Ruz N, Pérez-Ríos AM, Poo-Ramírez JL, Rizo-Robles MT, Sánchez-Ávila JF, Sandoval-Salas R, Torre A, Torres-Ibarra R, Trejo-Estrada R, Velarde-Ruiz Velasco JA, Wolpert-Barraza E, Bosques-Padilla F. The Mexican consensus on the treatment of hepatitis C. Rev Gastroenterol Mex (Engl Ed) 2018;83:275-324. [PMID: 29803325 DOI: 10.1016/j.rgmx.2017.11.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.8] [Reference Citation Analysis]
135 Namazee N, Sali S, Asadi S, Shafiei M, Behnava B, Alavian SM. Real response to therapy in chronic hepatitis C virus patients: a study from iran. Hepat Mon 2012;12:e6151. [PMID: 23087759 DOI: 10.5812/hepatmon.6151] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
136 Burstow NJ, Mohamed Z, Gomaa AI, Sonderup MW, Cook NA, Waked I, Spearman CW, Taylor-Robinson SD. Hepatitis C treatment: where are we now? Int J Gen Med 2017;10:39-52. [PMID: 28255252 DOI: 10.2147/IJGM.S127689] [Cited by in F6Publishing: 21] [Reference Citation Analysis]
137 Mcewan P, Selvapatt N, Brown A, Thursz M, Bennett H, Webster S, Kalsekar A, Yuan Y, Brenner M, Gordon J. A clinician’s guide to the cost and health benefits of hepatitis C cure assessed from the individual patient perspective: . European Journal of Gastroenterology & Hepatology 2017;29:208-14. [DOI: 10.1097/meg.0000000000000773] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
138 Wiznia LE, Laird ME, Franks AG Jr. Hepatitis C virus and its cutaneous manifestations: treatment in the direct-acting antiviral era. J Eur Acad Dermatol Venereol. 2017;31:1260-1270. [PMID: 28252812 DOI: 10.1111/jdv.14186] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
139 Bodeau S, Durand-maugard C, Lemaire-hurtel A, François C, Castelain S, Helle F, Andréjak M, Nguyen-khac E, Duverlie G, Brochot E. The End-of-Treatment Ribavirin Concentration Predicts Hepatitis C Virus Relapse. Therapeutic Drug Monitoring 2013;35:791-5. [DOI: 10.1097/ftd.0b013e3182966dee] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
140 Zeng QL, Zhang JY, Zhang Z, Wang LF, Wang FS. Sofosbuvir and ABT-450: Terminator of hepatitis C virus? World J Gastroenterol 2013; 19(21): 3199-3206 [PMID: 23745021 DOI: 10.3748/wjg.v19.i21.3199] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
141 Dejman A, Ladino MA, Roth D. Treatment and management options for the hepatitis C virus infected kidney transplant candidate. Hemodial Int 2018;22 Suppl 1:S36-44. [PMID: 29694726 DOI: 10.1111/hdi.12646] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
142 Brochot E, Riachi G, Plantier JC, Guillemard C, Vabret A, Mathurin P, Nguyen-Khac E, Duverlie G. Kinetics of relapse after pegylated interferon and ribavirin therapy for chronic hepatitis C. J Med Virol. 2013;85:1191-1198. [PMID: 23918537 DOI: 10.1002/jmv.23592] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
143 Li HC, Lo SY. Hepatitis C virus: Virology, diagnosis and treatment. World J Hepatol 2015; 7(10): 1377-1389 [PMID: 26052383 DOI: 10.4254/wjh.v7.i10.1377] [Cited by in Crossref: 76] [Cited by in F6Publishing: 52] [Article Influence: 10.9] [Reference Citation Analysis]
144 Majumdar A, Kitson MT, Roberts SK. Treatment of hepatitis C in patients with cirrhosis: remaining challenges for direct-acting antiviral therapy. Drugs 2015;75:823-34. [PMID: 25943281 DOI: 10.1007/s40265-015-0401-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
145 Liu CJ, Chen PJ. Updates on the treatment and outcomes of dual chronic hepatitis C and B virus infection. World J Gastroenterol 2014; 20(11): 2955-2961 [PMID: 24659886 DOI: 10.3748/wjg.v20.i11.2955] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
146 Tin K, Soe E, Park J. Management of Direct-Acting Antiviral Failures in Chronic Hepatitis C Infection. Curr Hepatology Rep 2016;15:296-306. [DOI: 10.1007/s11901-016-0326-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
147 Zeng QL, Li B, Zhang XX, Chen Y, Fu YL, Lv J, Liu YM, Yu ZJ. Clinical Model for Predicting Hepatocellular Carcinomas in Patients with Post-Sustained Virologic Responses of Chronic Hepatitis C: A Case Control Study. Gut Liver 2016;10:955-61. [PMID: 27257023 DOI: 10.5009/gnl15321] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
148 Loo N, Hanysak B, Mann J, Ramirez R, Kim J, Mitchell R, Van Frank T, Guerrero R, Hinojosa K, Christensen K, Pedicone LD, Alkhouri N, Wells J, Landaverde C, Rodas F, Lawitz E, Poordad F. Real-world observational experience with direct-acting antivirals for hepatitis C: baseline resistance, efficacy, and need for long-term surveillance. Medicine (Baltimore) 2019;98:e16254. [PMID: 31261592 DOI: 10.1097/MD.0000000000016254] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
149 Molina Pérez E, Fernández Castroagudín J, Domínguez Muñoz E. [Current indications for triple therapy in hepatitis C virus infection]. Gastroenterol Hepatol 2012;35:266-77. [PMID: 22410706 DOI: 10.1016/j.gastrohep.2012.01.003] [Reference Citation Analysis]
150 Hotho DM, de Bruijne J, Spaan M, Treitel MA, Boonstra A, de Knegt RJ, Janssen HL, Reesink HW. Sustained virologic response after therapy with the HCV protease inhibitor narlaprevir in combination with peginterferon and ribavirin is durable through long-term follow-up. J Viral Hepat 2013;20:e78-81. [PMID: 23490393 DOI: 10.1111/jvh.12012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
151 Lok AS, Chung RT, Vargas HE, Kim AY, Naggie S, Powderly WG. Comments on cochrane review on direct-acting antivirals for hepatitis C: Lok et al. Hepatology 2017;66:1016-9. [DOI: 10.1002/hep.29366] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
152 Höner zu Siederdissen C, Manns MP, Cornberg M. [Which treatment options are validated for chronic viral hepatitis?]. Internist (Berl) 2013;54:1427-8, 1430-3. [PMID: 24258199 DOI: 10.1007/s00108-013-3319-3] [Reference Citation Analysis]
153 Sulava E, Bergin S, Long B, Koyfman A. Elevated Liver Enzymes: Emergency Department-Focused Management. J Emerg Med 2017;52:654-67. [PMID: 27889359 DOI: 10.1016/j.jemermed.2016.10.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
154 Falade-Nwulia O, Sulkowski MS. Hepatitis C Virus Treatment: Simplifying the Simple and Optimizing the Difficult. J Infect Dis 2020;222:S745-57. [PMID: 33245350 DOI: 10.1093/infdis/jiaa534] [Reference Citation Analysis]
155 Liu CH, Kao JH. Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa. Int J Nanomedicine 2014;9:2051-67. [PMID: 24812506 DOI: 10.2147/IJN.S41822] [Cited by in Crossref: 1] [Cited by in F6Publishing: 11] [Article Influence: 0.1] [Reference Citation Analysis]
156 Islam N, Krajden M, Shoveller J, Gustafson P, Gilbert M, Buxton JA, Wong J, Tyndall MW, Janjua NZ. Incidence, risk factors, and prevention of hepatitis C reinfection: a population-based cohort study. The Lancet Gastroenterology & Hepatology 2017;2:200-10. [DOI: 10.1016/s2468-1253(16)30182-0] [Cited by in Crossref: 62] [Cited by in F6Publishing: 31] [Article Influence: 12.4] [Reference Citation Analysis]
157 Pearlman BL, Traub N. Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. Clin Infect Dis. 2011;52:889-900. [PMID: 21427396 DOI: 10.1093/cid/cir076] [Cited by in Crossref: 161] [Cited by in F6Publishing: 161] [Article Influence: 14.6] [Reference Citation Analysis]
158 Velosa J, Serejo F, Marinho R, Nunes J, Glória H. Eradication of hepatitis C virus reduces the risk of hepatocellular carcinoma in patients with compensated cirrhosis. Dig Dis Sci. 2011;56:1853-1861. [PMID: 21374066 DOI: 10.1007/s10620-011-1621-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
159 Karayiannis P. Direct acting antivirals for the treatment of chronic viral hepatitis. Scientifica (Cairo) 2012;2012:478631. [PMID: 24278700 DOI: 10.6064/2012/478631] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
160 Duddempudi AT, Bernstein DE. Hepatitis B and C. Clinics in Geriatric Medicine 2014;30:149-67. [DOI: 10.1016/j.cger.2013.10.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
161 Nguyen LH, Nguyen MH. Systematic review: Asian patients with chronic hepatitis C infection. Aliment Pharmacol Ther. 2013;37:921-936. [PMID: 23557103 DOI: 10.1111/apt.12300] [Cited by in Crossref: 89] [Cited by in F6Publishing: 84] [Article Influence: 9.9] [Reference Citation Analysis]
162 Elkhoudary MM, Selim BM, Abdelsalam RA, Hadad GM, El-gindy A. Development and validation of a simple HPTLC method for the determination of new hepatitis C subtype 4 antiviral agents in their tablet dosage form. JPC-J Planar Chromat 2020;33:71-7. [DOI: 10.1007/s00764-019-00006-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
163 Schønning K, Pedersen MS, Johansen K, Landt B, Nielsen LG, Weis N, Westh H. Analytical and clinical performance of the Hologic Aptima HCV Quant Dx Assay for the quantification of HCV RNA in plasma samples. J Virol Methods 2017;248:159-65. [PMID: 28732692 DOI: 10.1016/j.jviromet.2017.07.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
164 Chevaliez S. Antiviral activity of the new DAAs for the treatment of hepatitis C virus infection: virology and resistance. Clin Res Hepatol Gastroenterol 2011;35 Suppl 2:S46-51. [PMID: 22248694 DOI: 10.1016/S2210-7401(11)70007-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
165 Bang CS, Song IH. Impact of antiviral therapy on hepatocellular carcinoma and mortality in patients with chronic hepatitis C: systematic review and meta-analysis. BMC Gastroenterol 2017;17:46. [PMID: 28376711 DOI: 10.1186/s12876-017-0606-9] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]
166 Liu CJ, Chen PJ, Chen DS, Tseng TC, Kao JH. Perspectives on dual hepatitis B and C infection in Taiwan. J Formos Med Assoc 2016;115:298-305. [PMID: 26188762 DOI: 10.1016/j.jfma.2015.06.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
167 Korean Association for the Study of the Liver. KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol. 2016;22:76-139. [PMID: 27044763 DOI: 10.3350/cmh.2016.22.1.76] [Cited by in Crossref: 42] [Cited by in F6Publishing: 52] [Article Influence: 7.0] [Reference Citation Analysis]
168 Koh C, Heller T, Haynes-Williams V, Hara K, Zhao X, Feld JJ, Kleiner DE, Rotman Y, Ghany MG, Liang TJ, Hoofnagle JH. Long-term outcome of chronic hepatitis C after sustained virological response to interferon-based therapy. Aliment Pharmacol Ther 2013;37:887-94. [PMID: 23461575 DOI: 10.1111/apt.12273] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 4.1] [Reference Citation Analysis]
169 Airewele NE, Shiffman ML. Chronic Hepatitis B Virus in Patients with Chronic Hepatitis C Virus. Clin Liver Dis 2021;25:817-29. [PMID: 34593155 DOI: 10.1016/j.cld.2021.06.008] [Reference Citation Analysis]
170 Gorka S, Gulzar GM, Yattoo GN, Sodhi JS, Dar GA, Laway MA, Kaushik S, Dhar N, Mushfiq S, Aziz RA. Genotype 1 and 3 Response to Velpatasvir and Sofosbuvir in Chronic Hepatitis C in the Kashmiri Population: An Observational Study. J Clin Exp Hepatol 2020;10:155-62. [PMID: 32189931 DOI: 10.1016/j.jceh.2019.07.003] [Reference Citation Analysis]
171 Vo KP, Vutien P, Akiyama MJ, Vu VD, Ha NB, Piotrowski JI, Wantuck J, Roytman MM, Tsai N, Cheung R, Li J, Nguyen MH. Poor Sustained Virological Response in a Multicenter Real-Life Cohort of Chronic Hepatitis C Patients Treated with Pegylated Interferon and Ribavirin plus Telaprevir or Boceprevir. Dig Dis Sci 2015;60:1045-51. [DOI: 10.1007/s10620-015-3621-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
172 Choi SB, Lee YJ, Lee JI, Song YJ, Choi BJ, Kim JH, Jung EU, Park SJ, Lee SH, Kim JH, Choi JS, Jee SR, Seol SY. Durability of a sustained virological response in chronic hepatitis C patients treated with pegylated interferon alfa and ribavirin. Korean J Hepatol 2011;17:183-8. [PMID: 22102384 DOI: 10.3350/kjhep.2011.17.3.183] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
173 Scagnolari C, Turriziani O, Monteleone K, Pierangeli A, Antonelli G. Consolidation of molecular testing in clinical virology. Expert Rev Anti Infect Ther 2017;15:387-400. [PMID: 28002969 DOI: 10.1080/14787210.2017.1271711] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
174 Shi X, Jiao B, Chen Y, Li S, Chen L. MxA is a positive regulator of type I IFN signaling in HCV infection. J Med Virol 2017;89:2173-80. [PMID: 28561372 DOI: 10.1002/jmv.24867] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
175 Hsu Y, Wu C, Lin J. Hepatitis C Virus Infection, Antiviral Therapy, and Risk of Hepatocellular Carcinoma. Seminars in Oncology 2015;42:329-38. [DOI: 10.1053/j.seminoncol.2014.12.023] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
176 Sagnelli E, Sagnelli C, Pisaturo M, Coppola N. Hepatic flares in chronic hepatitis C: Spontaneous exacerbation vs hepatotropic viruses superinfection. World J Gastroenterol 2014; 20(22): 6707-6715 [PMID: 24944463 DOI: 10.3748/wjg.v20.i22.6707] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
177 Gutierrez JA, Lawitz EJ, Poordad F. Interferon-free, direct-acting antiviral therapy for chronic hepatitis C. J Viral Hepat. 2015;22:861-870. [PMID: 26083155 DOI: 10.1111/jvh.12422] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 8.0] [Reference Citation Analysis]
178 Ponziani FR, Viganò R, Iemmolo RM, Donato MF, Rendina M, Toniutto P, Pasulo L, Morelli MC, Burra P, Miglioresi L. Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C. Dig Liver Dis. 2014;46:440-445. [PMID: 24635906 DOI: 10.1016/j.dld.2014.01.157] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
179 Aghemo A, Degasperi E, De Nicola S, Bono P, Orlandi A, D’ambrosio R, Soffredini R, Perbellini R, Lunghi G, Colombo M. Quantification of Core Antigen Monitors Efficacy of Direct-acting Antiviral Agents in Patients With Chronic Hepatitis C Virus Infection. Clinical Gastroenterology and Hepatology 2016;14:1331-6. [DOI: 10.1016/j.cgh.2016.03.035] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
180 Berenguer J, Alvarez-pellicer J, Carrero A, Von Wichmann MA, López-aldeguer J, Mallolas J, Galindo MJ, Van Den Eynde E, Téllez MJ, Quereda C, Tural C, Sanz J, Barros C, Santos I, Pulido F, Guardiola JM, Ortega E, Rubio R, Jusdado JJ, Montes ML, Gaspar G, Barquilla E, Bellón JM, González-garcía J. Clinical effects of viral relapse after interferon plus ribavirin in patients co-infected with human immunodeficiency virus and hepatitis C virus. Journal of Hepatology 2013;58:1104-12. [DOI: 10.1016/j.jhep.2013.01.042] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
181 Shiffman ML. The next wave of hepatitis C virus: The epidemic of intravenous drug use. Liver Int 2018;38:34-9. [DOI: 10.1111/liv.13647] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
182 Mahale P, Okhuysen PC, Torres HA. Does Chemotherapy Cause Viral Relapse in Cancer Patients With Hepatitis C Infection Successfully Treated With Antivirals? Clinical Gastroenterology and Hepatology 2014;12:1051-1054.e1. [DOI: 10.1016/j.cgh.2013.10.034] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
183 Di Marco V, D'Ambrosio R, Bronte F, Saracco G, Lanza AG, Forni G, Poggiali E, Calvaruso V; on behalf ITHACA (Italy for THAalassemia, hepatitis C Advances) Group. Dual therapy with peg-interferon and ribavirin in thalassemia major patients with chronic HCV infection: Is there still an indication? Dig Liver Dis 2016;48:650-5. [PMID: 27012446 DOI: 10.1016/j.dld.2016.02.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
184 Zeuzem S. Treatment Options in Hepatitis C. Dtsch Arztebl Int 2017;114:11-21. [PMID: 28143635 DOI: 10.3238/arztebl.2017.0011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
185 Abd Elrazek AE, Bilasy SE, Elbanna AE, Elsherif AE. Prior to the oral therapy, what do we know about HCV-4 in Egypt: a randomized survey of prevalence and risks using data mining computed analysis. Medicine (Baltimore). 2014;93:e204. [PMID: 25526438 DOI: 10.1097/md.0000000000000204] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
186 Shiffman ML, Benhamou Y. Cure of HCV related liver disease. Liver Int 2015;35 Suppl 1:71-7. [PMID: 25529090 DOI: 10.1111/liv.12734] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
187 Upadya MH, Aweya JJ, Tan YJ. Understanding the interaction of hepatitis C virus with host DEAD-box RNA helicases. World J Gastroenterol 2014; 20(11): 2913-2926 [PMID: 24659882 DOI: 10.3748/wjg.v20.i11.2913] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
188 Yu ML, Lee CM, Chen CL, Chuang WL, Lu SN, Liu CH, Wu SS, Liao LY, Kuo HT, Chao YC. Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up. Hepatology. 2013;57:2135-2142. [PMID: 23322699 DOI: 10.1002/hep.26266] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 5.6] [Reference Citation Analysis]
189 Park SH, Bang CS, Kim DJ. Biomarkers in HCV Infection. Adv Clin Chem 2015;70:131-96. [PMID: 26231487 DOI: 10.1016/bs.acc.2015.03.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
190 Sinakos E, Vlachaki E, Tsapas A. Safety of deferasirox in sickle cell disease patients with co-existing liver impairment. Br J Haematol 2012;157:505-6; author reply 506-7. [PMID: 22299817 DOI: 10.1111/j.1365-2141.2012.09040.x] [Reference Citation Analysis]
191 Manns MP, Pockros PJ, Norkrans G, Smith CI, Morgan TR, Häussinger D, Shiffman ML, Hadziyannis SJ, Schmidt WN, Jacobson IM. Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirin. J Viral Hepat. 2013;20:524-529. [PMID: 23808990 DOI: 10.1111/jvh.12074] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 6.7] [Reference Citation Analysis]
192 Hajarizadeh B, Cunningham EB, Valerio H, Martinello M, Law M, Janjua NZ, Midgard H, Dalgard O, Dillon J, Hickman M, Bruneau J, Dore GJ, Grebely J. Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis. Journal of Hepatology 2020;72:643-57. [DOI: 10.1016/j.jhep.2019.11.012] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 13.5] [Reference Citation Analysis]
193 Pawlotsky J, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, Marra F, Puoti M, Wedemeyer H. EASL recommendations on treatment of hepatitis C: Final update of the series☆. Journal of Hepatology 2020;73:1170-218. [DOI: 10.1016/j.jhep.2020.08.018] [Cited by in Crossref: 113] [Cited by in F6Publishing: 102] [Article Influence: 56.5] [Reference Citation Analysis]
194 Alqahtani SA, Colombo MG. Treating paediatric hepatitis C in the era of direct-acting antiviral agents. Liver Int 2021;41:1189-200. [PMID: 33533543 DOI: 10.1111/liv.14810] [Reference Citation Analysis]
195 Chen J, Florian J, Carter W, Fleischer RD, Hammerstrom TS, Jadhav PR, Zeng W, Murray J, Birnkrant D. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology. 2013;144:1450-1455.e2. [PMID: 23470616 DOI: 10.1053/j.gastro.2013.02.039] [Cited by in Crossref: 114] [Cited by in F6Publishing: 105] [Article Influence: 12.7] [Reference Citation Analysis]
196 Shah H, Bilodeau M, Burak KW, Cooper C, Klein M, Ramji A, Smyth D, Feld JJ; Canadian Association for the Study of the Liver. The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver. CMAJ 2018;190:E677-87. [PMID: 29866893 DOI: 10.1503/cmaj.170453] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 16.7] [Reference Citation Analysis]
197 Jacobson IM, Lim JK, Fried MW. American Gastroenterological Association Institute Clinical Practice Update-Expert Review: Care of Patients Who Have Achieved a Sustained Virologic Response After Antiviral Therapy for Chronic Hepatitis C Infection. Gastroenterology. 2017;152:1578-1587. [PMID: 28344022 DOI: 10.1053/j.gastro.2017.03.018] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 9.8] [Reference Citation Analysis]
198 McEwan P, Ward T, Bennett H, Kalsekar A, Webster S, Brenner M, Yuan Y. Estimating the clinical and economic benefit associated with incremental improvements in sustained virologic response in chronic hepatitis C. PLoS One 2015;10:e0117334. [PMID: 25635922 DOI: 10.1371/journal.pone.0117334] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
199 Feld JJ. Treatment indication and response to standard of care with peginterferon and ribavirin in acute and chronic HCV infection. Best Practice & Research Clinical Gastroenterology 2012;26:429-44. [DOI: 10.1016/j.bpg.2012.09.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
200 Jothimani D, Chandy GM, Conjeevaram H. A new era in the treatment of chronic hepatitis C infection. Indian J Gastroenterol 2013;32:71-9. [PMID: 23054947 DOI: 10.1007/s12664-012-0254-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
201 Hayashi K, Ishigami M, Yasuda S, Ishizu Y, Kuzuya T, Honda T, Ishikawa T, Hirooka Y, Goto H. Occurrence of late relapse of hepatitis C virus confirmed by molecular analysis after sustained virologic response to interferon-ribavirin-based therapy. Hepatol Res 2018;48:E78-86. [PMID: 28643404 DOI: 10.1111/hepr.12929] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
202 Powderly WG, Naggie S, Kim AY, Vargas HE, Chung RT, Lok AS. IDSA/AASLD Response to Cochrane Review on Direct-Acting Antivirals for Hepatitis C. Clinical Infectious Diseases 2017;65:1773-5. [DOI: 10.1093/cid/cix620] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
203 Buti M, Homs M. Nuevos agentes para el tratamiento de la hepatitis C. Enfermedades Infecciosas y Microbiología Clínica 2012;30:147-50. [DOI: 10.1016/j.eimc.2011.09.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
204 Feeney ER, Chung RT. Antiviral treatment of hepatitis C. BMJ. 2014;348:g3308. [PMID: 25002352 DOI: 10.1136/bmj.g3308] [Cited by in Crossref: 142] [Cited by in F6Publishing: 135] [Article Influence: 17.8] [Reference Citation Analysis]
205 Maan R, van der Meer AJ. Recent advances in managing chronic HCV infection: focus on therapy in patients with severe liver disease. F1000Res 2016;5:F1000 Faculty Rev-367. [PMID: 27006761 DOI: 10.12688/f1000research.7399.1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
206 Sims OT, Whalen CC, Nackerud LG, Bride BE. Birth cohort testing for hepatitis C virus: implications for clinical social workers in health care settings. Soc Work Health Care 2013;52:689-703. [PMID: 24028735 DOI: 10.1080/00981389.2013.806385] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
207 Jesudian AB, de Jong YP, Jacobson IM. Emerging therapeutic targets for hepatitis C virus infection. Clin Gastroenterol Hepatol 2013;11:612-9.e1. [PMID: 23583900 DOI: 10.1016/j.cgh.2013.04.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]